|
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC) In early-phase trials, nivolumab-based neoadjuvant regimens
- Nivolumab in the treatment of metastatic squamous non-small cell lung . . .
Abstract Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab
- Nivolumab Approved for Neoadjuvant and Adjuvant Treatment of Non-small . . .
The immunotherapy is now approved to treat certain lung cancers before and after surgery The U S Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone, for patients with non-small cell lung cancer (NSCLC) that can be surgically removed, is 4 cm or larger or has spread to the lymph nodes, and
- Non-Small Cell Lung Cancer (NSCLC) Treatment | OPDIVO® (nivolumab)
OPDIVO® (nivolumab) alone, or with YERVOY® (ipilimumab) can be used as an immunotherapy treatment option for adults with certain types of NSCLC Please see Indication and Important Safety Information
- Update to ASCO Living Guideline for NSCLC Without Driver Alterations . . .
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer without driver alterations based on results of 3 phase 3 studies published recently: NIPPON, HARMONi-2, and DUBLIN-3 It also includes a discussion of immunotherapy options and other agents, including ivonescimab and plinabulin
- FDA Approves Perioperative Nivolumab for Resectable NSCLC
The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC
- Nivolumab plus ipilimumab versus carboplatin-based doublet as first . . .
Background: Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or those with an ECOG performance status of 2
- Nivolumab and Chemotherapy for Early-Stage Lung Cancer
In the CheckMate 816 trial, people with early-stage non-small cell lung cancer (stage IB to IIIA) received either nivolumab (Opdivo) and chemotherapy or chemotherapy alone before surgery
|
|
|